COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-Versus-Host Disease (sr-aGvHD)

Protocol No
ABGENOMICS-2017-002-01
Principal Investigator
Sameem Abedin
Phase
I
Summary
To understand the pharmacokinetic (PK) profile of the study drug in patients who have developed aGvHD following a stem cell transplant.
Description
Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL